Clearside Biomedical (CLSDQ) investor relations material

Executive summary

• Focused on suprachoroidal space (SCS) drug delivery, with XIPERE as the first FDA-approved product for uveitic macular edema.

• In July 2025, initiated a strategic review, including potential sale, licensing, or other transactions, and transitioned all employees to consulting roles.

• Paused all internal R&D programs to conserve cash while seeking strategic alternatives.

Financial highlights

• Net loss of $5.97 million for Q3 2025, improved from $7.69 million in Q3 2024; net loss of $18.69 million for the nine months ended September 30, 2025, versus $27.05 million in the prior year period.

• License and other revenue was $0.2 million for Q3 2025, down from $1.0 million in Q3 2024; $3.0 million for the nine months, up from $1.4 million in 2024.

• Cash and cash equivalents were $6.8 million as of September 30, 2025, down from $20.0 million at year-end 2024.

• Operating cash outflow was $16.0 million for the nine months ended September 30, 2025.

Outlook and guidance

• Current cash is insufficient to fund operations for the next 12 months; substantial doubt exists about the ability to continue as a going concern.

• Exploring strategic alternatives; if unsuccessful, may need to file for bankruptcy or wind down operations.

• All internal R&D paused; future activities depend on additional capital or successful strategic transaction.